SP1 and Miyoshi myopathy: Importantly, genetic as well as pharmacological targeting of Sp1 was able to reduce tumor growth both in vitro and in vivo,6, 8 thus indicating that Sp1 is a suitable target for therapeutic intervention in MM and WM.